Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This product is the plasmid containing an encoded anti-CDKN2A DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.
| Sub CAT. | DMAb Clone | DMAb Host | Target Species | DMAb Isotype | DMAb Immunogen | |
| DMAb-0412-WJ | CBWJC-0310 | Rabbit | Human | IgG | ||
| DMAb-0413-WJ | CBWJC-0311 | Rabbit | Human | IgG | ||
| DMAb-0414-WJ | CBWJC-1899 | Mouse | Human | IgG1 | ||
| DMAb-0415-WJ | CBWJC-1900 | Mouse | Human | IgG1 | ||
| DMAb-0416-WJ | CBWJC-1901 | Mouse | Human | IgG2a | ||
| DMAb-0417-WJ | CBWJC-1902 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0418-WJ | CBWJC-1903 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0419-WJ | CBWJC-1904 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0420-WJ | CBWJC-1905 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0421-WJ | CBWJC-1906 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0422-WJ | CBWJC-1907 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0423-WJ | CBWJC-1908 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E.coli | |
| DMAb-0424-WJ | CBWJC-1909 | Mouse | Human | IgG1 | Human recombinant protein fragment corresponding to AA 25-156 of human CDKN2A (NP_478102) produced in E.coli | |
| DMAb-0425-WJ | CBWJC-1910 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in HEK293T cell | |
| DMAb-0426-WJ | CBWJC-1911 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0427-WJ | CBWJC-1912 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0428-WJ | CBWJC-1913 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0429-WJ | CBWJC-1914 | Mouse | Human | IgG1 | Human recombinant protein fragment corresponding to AA 25-156 of human CDKN2A (NP_478102) produced in E.coli | |
| DMAb-0430-WJ | CBWJC-1915 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E.coli | |
| DMAb-0431-WJ | CBWJC-1916 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E.coli | |
| DMAb-0432-WJ | CBWJC-1917 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E.coli | |
| DMAb-0433-WJ | CBWJC-1918 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0434-WJ | CBWJC-1919 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0435-WJ | CBWJC-1920 | Mouse | Human | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli | |
| DMAb-0436-WJ | CBWJC-1921 | Mouse | Human | IgG1 | ||
| DMAb-0437-WJ | CBWJC-1922 | Mouse | Human | IgG1 | Recombinant human p16 protein | |
| DMAb-0438-WJ | CBWJC-1923 | Mouse | Human | IgG1 | A recombinant full length CDKN2A protein recognizing a 16kDa protein | |
| DMAb-0439-WJ | CBWJC-1924 | Rabbit | Human | IgG | ||
| DMAb-0440-WJ | CBWJC-1925 | Rabbit | Human | IgG | ||
| DMAb-0441-WJ | CBWJC-1926 | Mouse | Human | IgG2a | ||
| DMAb-0432-CQ | CBXC-2422 | Mouse | IgG1, κ | |||
| DMAb-0433-CQ | CBXC-0344 | Mouse | IgG1 | |||
| DMAb-0434-CQ | CBXC-2030 | Mouse | IgG1 | |||
| DMAb-0435-CQ | CBXC-2199 | Mouse | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E. coli | ||
| DMAb-0436-CQ | CBXC-2409 | Mouse | IgG1 | Full length human recombinant protein of human CDKN2A(NP_000068) produced in E. coli | ||
| DMAb-0437-CQ | CBXC-2966 | Mouse | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E. coli | ||
| DMAb-0438-CQ | CBXC-2568 | Mouse | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E. coli | ||
| DMAb-0439-CQ | CBXC-2737 | Mouse | IgG2b | |||
| DMAb-0440-CQ | CBXC-2390 | Mouse | IgG1 | |||
| DMAb-0441-CQ | CBXC-2699 | Mouse | IgG1 | Full length human recombinant protein of human CDKN2A (NP_000068) produced in E. coli | ||
| DMAb-0442-CQ | CBXC-2872 | Mouse | IgG1 | |||
| DMAb-0443-CQ | CBXC-0345 | Mouse | IgG1 | |||
| DMAb-0444-CQ | CBXC-0346 | Mouse | IgG2a | |||
| DMAb-0445-CQ | CBXC-0343 | Mouse | IgG1 | Recombinant human CDKN2A | ||
| DMAb-0446-CQ | CBXC-2505 | Mouse | IgG1 | Ni-NTA purified truncated recombinant P16 expressed in E. coli strain BL21 (DE3) | ||
| DMAb-2838-FY | CBFYC-1635 | Rat | Mouse | IgG2b | ||
| DMAb-2839-FY | CBFYC-1636 | Mouse | Human | IgG1 | ||
| DMAb-2840-FY | CBFYC-1637 | Mouse | Human | IgG2b, k | Full-length human CDKN2A recombinant protein expressed in E. coli | |
| DMAb-2841-FY | CBFYC-1638 | Mouse | Human | IgG1, k | Full-length recombinant corresponding to aa1-580 from human CARF with GST tag. MW of the GST tag alone is 26kD. | |
| DMAb-2842-FY | CBFYC-1639 | Rat | Mouse | IgG2b | ||
| DMAb-2843-FY | CBFYC-1640 | Mouse | Human | IgG1 | ||
| DMAb-2844-FY | CBFYC-1641 | Mouse | Human | IgG1, k | ||
| DMAb-1087-YY | 5-C3 | Mouse | Mouse | IgG2b | ||
| DMAb-1169-YY | CBYY-C1804 | Mouse | Human | IgG1 | ||
| DMAb-1170-YY | CBYY-C1805 | Mouse | Human | IgG2a, κ | ||
| DMAb-1171-YY | CBYY-C1806 | Mouse | Human | IgG1 | ||
| DMAb-1172-YY | CBYY-C1807 | Mouse | Human | IgG1 | ||
| DMAb-1173-YY | CBYY-C1808 | Mouse | Human | IgG1 |
There are currently no customer reviews or questions for Anti-CDKN2A DNA-encoded mAb (DMAb), pVAX1 (DMAb-0412-WJ). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
